Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-2,075
Closed -$235K 357
2024
Q2
$235K Buy
2,075
+207
+11% +$26.2K 0.01% 318
2024
Q1
$259K Sell
1,868
-130
-7% -$16.3K 0.01% 319
2023
Q4
$248K Buy
+1,998
New +$204K 0.01% 311
2023
Q3
Sell
-2,023
Closed -$260K 333
2023
Q2
$260K Sell
2,023
-360
-15% -$43.5K 0.01% 307
2023
Q1
$277K Sell
2,383
-30
-1% -$3.36K 0.01% 307
2022
Q4
$273K Buy
+2,413
New +$265K 0.01% 320
2022
Q2
Sell
-2,636
Closed -$337K 402
2022
Q1
$337K Sell
2,636
-236
-8% -$25.8K 0.01% 322
2021
Q4
$386K Sell
2,872
-8
-0.3% -$1.15K 0.01% 308
2021
Q3
$394K Sell
2,880
-1,520
-35% -$192K 0.01% 306
2021
Q2
$470K Sell
4,400
-460
-9% -$44.2K 0.01% 293
2021
Q1
$437K Sell
4,860
-460
-9% -$43.2K 0.01% 309
2020
Q4
$492K Buy
5,320
+2,460
+86% +$220K 0.02% 286
2020
Q3
$295K Buy
2,860
+480
+20% +$50.1K 0.01% 360
2020
Q2
$241K Buy
+2,380
New +$213K 0.01% 389

Other funds holding DXCM

Conning Inc's DXCM Position: Q3 2024 in Review

Conning Inc sold out of DexCom (DXCM) in Q3 2024, closing a stake of 2,075 shares — an estimated $235K sold.

Conning Inc first reported a position in DXCM in Q2 2020 and held it in 14 quarters. The position peaked at $492K in Q4 2020. 889 funds tracked by Wall St. Rank hold DXCM as of Q3 2024.

  • Conning Inc reported no remaining DexCom position as of Q3 2024 after selling out during the quarter.
  • Conning Inc sold 2,075 DexCom shares in Q3 2024, an estimated $235K.
  • Conning Inc first reported a position in DexCom in Q2 2020 and held it in 14 quarters.
  • Conning Inc's DexCom position peaked at $492K in Q4 2020.
  • 889 funds tracked by Wall St. Rank held DexCom as of Q3 2024.

Based on Conning Inc's 13F filing for Q3 2024, filed 29 Oct 2024.